Physician profile
Brian Zembower
NPI 1922490382
$1,526.39
in general payments reported to CMS, 2019-2025
13 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2021: $33.10 · 2022: $377 · 2023: $50.21 · 2024: $473 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.68 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $198.11 | 2024 | |
| Glaukos Corporation | $176.52 | 2024-2025 | Idose, Idosetr |
| Abbvie INC. | $174.35 | 2022-2025 | Alphagan P, Lumigan |
| Alcon Vision LLC | $166.04 | 2019-2025 | Tryptyr, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $158.77 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $124.85 | 2022 | |
| Allergan, INC. | $121.65 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $120.82 | 2019 | |
| Dompe US, INC. | $110.43 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $62.82 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $41.29 | 2023-2024 | Ic-8 Apthera Iol, Infuse |
| Rxsight INC | $39.39 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $31.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Zembower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.